Literature DB >> 2690635

Estrogen replacement therapy: indications, contraindications, and agent selection.

M Notelovitz1.   

Abstract

Three groups of indications exist for postmenopausal estrogen use: relief of symptoms related to estrogen deficiency, osteoporosis prophylaxis and treatment, and cardioprotection. Estrogen replacement therapy enhances a woman's sense of well-being and reduces the morbidity, mortality, and health care costs associated with osteoporosis and atherosclerotic heart disease. There are a few absolute contraindications to estrogen replacement therapy. Many estrogen preparations are currently available in the United States. Establishing equivalencies among the different preparations is complicated by the many physiologic and pharmacologic effects of estrogens and the variety of treatment end points used. Most estrogens have the same biologic effect provided equivalent blood levels are achieved. Estrogen replacement therapy has proved beneficial to selected postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690635     DOI: 10.1016/s0002-9378(89)80003-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

Review 1.  Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives.

Authors:  Nancy Krieger; Ilana Löwy; Robert Aronowitz; Judyann Bigby; Kay Dickersin; Elizabeth Garner; Jean-Paul Gaudillière; Carolina Hinestrosa; Ruth Hubbard; Paula A Johnson; Stacey A Missmer; Judy Norsigian; Cynthia Pearson; Charles E Rosenberg; Lynn Rosenberg; Barbara G Rosenkrantz; Barbara Seaman; Carlos Sonnenschein; Ana M Soto; Joe Thornton; George Weisz
Journal:  J Epidemiol Community Health       Date:  2005-09       Impact factor: 3.710

2.  Localization of estrogen receptors in long bones and vertebrae of human fetuses.

Authors:  H Ben-Hur; G Mor; I Blickstein; I Likhman; F Kohen; R Dgani; V Insler; P Yaffe; A Ornoy
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

3.  Vagifem is superior to vaginal Premarin in induction of endometrial thickness in the frozen-thawed cycle patients with refractory endometria: A randomized clinical trial.

Authors:  Jaleh Zolghadri; Hossein Haghbin; Nasrin Dadras; Shabnam Behdin
Journal:  Iran J Reprod Med       Date:  2014-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.